Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01081951 · ClinicalTrials.gov registry record · Phase 2
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
A Phase 2 study of Ovarian Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
- 20
- Study locations
NCT01081951: Active Phase 2 study of Ovarian Cancer, sponsored by AstraZeneca.
NCT01081951 is a Phase 2 study of Ovarian Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 162 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01081951, a Phase 2 study of Ovarian Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.
Primary Outcome
PFS (based on independent central review) was defined as the time from randomisation until objective disease progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 (≥20% increase in the sum of the diameters of target lesions from minimum, clinically significant progression in non-target lesions or the presence of a new lesion) or death (by any cause in the absence of progression).
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG olaparib
- DRUG Drug: carboplatin
Study Locations (20)
Other
- Research Site - Parkville
- Research Site - Randwick
- Research Site - Brussels
- Research Site - Leuven
- Research Site - Namur
- Research Site - Wilrijk
Ontario
- Research Site - Hamilton
- Research Site - Toronto
- Research Site - Toronto
California
- Research Site - Stanford
- Research Site - West Hollywood
Massachusetts
- Research Site - Boston
- Research Site - Boston
Quebec
- Research Site - Québec
- Research Site - Sherbrooke
Florida
- Research Site - Orlando
Indiana
- Research Site - Indianapolis
New York
- Research Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2010-02-04 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT01081951 still lists
NCT01081951 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.
NCT01081951 names 20 study sites across 10 states, led by Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT01081951 about?
NCT01081951 is a clinical study titled "Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer". To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.
What is the current status of trial NCT01081951?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2010-02-04. Estimated completion is 2026-12-31.
What conditions does trial NCT01081951 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT01081951?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), olaparib (DRUG), Drug: carboplatin (DRUG).
Who is sponsoring clinical trial NCT01081951?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01081951 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01081951's enrollment target sits among peer trials
162 116th of 322 higher than 207 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI